Notice2022-20042
Certain Plant-Derived Recombinant Human Serum Albumins (“rHSA”) and Products Containing Same; Notice of the Commission's Final Determination Finding a Violation of Section 337; Issuance of a Limited Exclusion Order and Cease and Desist Orders; Termination of the Investigation
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
September 16, 2022
Issuing agencies
International Trade Commission
Abstract
Notice is hereby given that the U.S. International Trade Commission has found a violation of section 337 in the above-captioned investigation. The Commission has determined to issue: (1) a limited exclusion order ("LEO") prohibiting the unlicensed entry of infringing plant-derived recombinant human serum albumins ("rHSA") and products containing the same covered by certain claims of U.S. Patent No. 10,618,951 that are manufactured by or on behalf of, or imported by or on behalf of, respondents Wuhan Healthgen Biotechnology Corp. ("Healthgen"); ScienCell Research Laboratories, Inc. ("ScienCell"); Aspira Scientific, Inc. ("Aspira"); and eEnzyme LLC ("eEnzyme") or any of their affiliated companies, parents, subsidiaries, or other related business entities, or their successors or assigns; and the entry of plant-derived rHSAs and products containing the same that include a false designation of origin that are manufactured by or on behalf of, or imported by or on behalf of, ScienCell, Aspira, or eEnzyme or any of their affiliated companies, parents, subsidiaries, agents, or other related business entities, or their successors or assigns; and (2) cease and desist orders ("CDOs") directed against ScienCell, Aspira, and eEnzyme, and any of their affiliated companies, parents, subsidiaries, or other related business entities, or their successors or assigns. This investigation is terminated.
Full Text
<html>
<head>
<title>Federal Register, Volume 87 Issue 179 (Friday, September 16, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 179 (Friday, September 16, 2022)]
[Notices]
[Pages 56982-56983]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2022-20042]
[[Page 56982]]
-----------------------------------------------------------------------
INTERNATIONAL TRADE COMMISSION
[Investigation No. 337-TA-1238]
Certain Plant-Derived Recombinant Human Serum Albumins (``rHSA'')
and Products Containing Same; Notice of the Commission's Final
Determination Finding a Violation of Section 337; Issuance of a Limited
Exclusion Order and Cease and Desist Orders; Termination of the
Investigation
AGENCY: International Trade Commission.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Notice is hereby given that the U.S. International Trade
Commission has found a violation of section 337 in the above-captioned
investigation. The Commission has determined to issue: (1) a limited
exclusion order (``LEO'') prohibiting the unlicensed entry of
infringing plant-derived recombinant human serum albumins (``rHSA'')
and products containing the same covered by certain claims of U.S.
Patent No. 10,618,951 that are manufactured by or on behalf of, or
imported by or on behalf of, respondents Wuhan Healthgen Biotechnology
Corp. (``Healthgen''); ScienCell Research Laboratories, Inc.
(``ScienCell''); Aspira Scientific, Inc. (``Aspira''); and eEnzyme LLC
(``eEnzyme'') or any of their affiliated companies, parents,
subsidiaries, or other related business entities, or their successors
or assigns; and the entry of plant-derived rHSAs and products
containing the same that include a false designation of origin that are
manufactured by or on behalf of, or imported by or on behalf of,
ScienCell, Aspira, or eEnzyme or any of their affiliated companies,
parents, subsidiaries, agents, or other related business entities, or
their successors or assigns; and (2) cease and desist orders (``CDOs'')
directed against ScienCell, Aspira, and eEnzyme, and any of their
affiliated companies, parents, subsidiaries, or other related business
entities, or their successors or assigns. This investigation is
terminated.
FOR FURTHER INFORMATION CONTACT: Ronald A. Traud, Esq., Office of the
General Counsel, U.S. International Trade Commission, 500 E Street SW,
Washington, DC 20436, telephone (202) 205-3427. Copies of non-
confidential documents filed in connection with this investigation may
be viewed on the Commission's electronic docket (EDIS) at <a href="https://edis.usitc.gov">https://edis.usitc.gov</a>. For help accessing EDIS, please email
<a href="/cdn-cgi/l/email-protection#3277767b61017a575e427247415b46511c555d44"><span class="__cf_email__" data-cfemail="db9e9f9288e893beb7ab9baea8b2afb8f5bcb4ad">[email protected]</span></a>. General information concerning the Commission may
also be obtained by accessing its internet server at <a href="https://www.usitc.gov">https://www.usitc.gov</a>. Hearing-impaired persons are advised that information on
this matter can be obtained by contacting the Commission's TDD terminal
on (202) 205-1810.
SUPPLEMENTARY INFORMATION: The Commission instituted this investigation
on January 25, 2021, based on a complaint filed on behalf of Ventria
Bioscience Inc. (``Ventria'') of Junction City, Kansas. 86 FR 6916
(Jan. 25, 2021). The complaint, as supplemented, alleged violations of
section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337,
based upon the importation into the United States, the sale for
importation, and the sale within the United States after importation of
certain plant-derived rHSA and products containing the same by reason
of infringement of certain claims of U.S. Patent Nos. 10,618,951 (``the
'951 patent'') and 8,609,416 (``the '416 patent''). Id. The complaint
also alleged violations of section 337 based on the importation into
the United States, or in the sale of, certain plant-derived rHSA and
products containing the same by reason of false designation of origin,
the threat or effect of which is to destroy or substantially injure an
industry in the United States. Id. The notice of investigation named
four respondents: Healthgen of Wuhan, China; ScienCell of Carlsbad,
California; Aspira of Milpitas, California; and eEnzyme of
Gaithersburg, Maryland (collectively, the ``Respondents''). Id. at
6917. The Office of Unfair Import Investigations (``OUII'') was also
named as a party in this investigation. Id.
Of the four Respondents named in the notice of investigation, only
Healthgen participated in the investigation. ScienCell, Aspira, and
eEnzyme were found in default. See Order No. 13 (July 28, 2021),
unreviewed by Comm'n Notice (Aug. 18, 2021). ScienCell, Aspira, and
eEnzyme are collectively referred to herein as the ``Defaulting
Respondents.''
Prior to the issuance of the final ID, the investigation terminated
as to all asserted claims of the '416 patent, claims 2 and 3 of the
'951 patent, and the false designation of origin claims against
Healthgen. See Order No. 12 (July 16, 2021), unreviewed by Comm'n
Notice (Aug. 10, 2021); Order No. 29 (Nov. 3, 2021), unreviewed by
Comm'n Notice (Nov. 29, 2021). The false designation of origin claims
against the Defaulting Respondents were not terminated. See Order No.
12 at 1. Accordingly, at the time the final ID issued, only claims 1
and 11-13 of the '951 patent remained pending against Healthgen, and
only claims 1 and 11-13 of the '951 patent and the false designation of
origin (or Lanham Act) claims remained pending against the Defaulting
Respondents.
On April 7, 2022, the ALJ issued the final ID, which found that
Respondents violated section 337. The ALJ found a violation of section
337 under section 337(a)(1)(B) by Healthgen as to infringement of the
'951 patent and found the requirements of section 337(g)(1) met as to
infringement of the '951 patent and the Lanham Act claim with respect
to the Defaulting Respondents.
The final ID included the ALJ's recommendation on remedy, the
public interest, and bonding (the ``RD''). The RD recommended that, if
the Commission finds a violation of section 337, the Commission should
issue a limited exclusion order against Healthgen and the Defaulting
Respondents, cease and desist orders against the Defaulting
Respondents, and impose a bond of one hundred percent (100%) of entered
value during the period of Presidential review.
On April 19, 2022, Healthgen filed a petition for review of the
final ID. On April 22, 2022, OUII filed a response to Healthgen's
petition, and on April 27, 2022, Ventria filed a response to
Healthgen's petition. On May 9, 2022, Ventria and Healthgen filed their
public interest comments pursuant to Commission Rule 210.50(a)(4) (19
CFR 210.50(a)(4)). The Commission also received several submissions
from third parties in response to the Commission's Federal Register
notice seeking comment on the public interest. 87 FR 21923-24 (Apr. 13,
2022).
On June 6, 2022, after considering the petition and responses
thereto, the Commission determined to review the final ID in its
entirety. 87 FR 35570-72 (June 10, 2022). The Commission requested
briefing on the issues under review and on remedy, the public interest,
and bonding. Id.
On review, and as explained in the simultaneously-issued Commission
opinion, the Commission has determined that there has been a violation
of section 337 with respect to the Asserted Patent by respondent Wuhan
Healthgen Biotechnology Corp. (``Healthgen'') and that the requirements
of section 337(g)(1) are met as to the defaulting respondents based on
a violation of section 337 alleged in the complaint with respect to
both the Asserted Patent claims and the Lanham Act claim. As to
Ventria's allegations of a section 337 violation based on
[[Page 56983]]
infringement of the '951 patent, Ventria has shown such a violation
only as to the clinical grade products. (Commissioner Stayin does not
join the Commission's determination as to medium grade products and
would find a violation as to all accused products.)
The Commission has determined that the appropriate form of relief
is a limited exclusion order prohibiting (1) the unlicensed entry of
infringing plant-derived recombinant human serum albumins (``rHSA'')
and products containing the same manufactured by or on behalf of, or
imported by or on behalf of, Healthgen or the Defaulting Respondents or
any of their affiliated companies, parents, subsidiaries, agents, or
other related business entities, or their successors or assigns; and
(2) the entry of plant-derived recombinant human serum albumins
(``rHSA'') and products containing same that fail to accurately
designate the country of origin, and which are manufactured abroad by
or on behalf of, or imported by or on behalf of, the Defaulting
Respondents or any of their affiliated companies, parents,
subsidiaries, agents, or other related business entities, or their
successors or assigns. The Commission has determined to issue cease and
desist orders against respondents ScienCell, Aspira, and eEnzyme.
The Commission has further determined that the public interest
factors enumerated in subsections (d)(l) and (g)(1) (19 U.S.C.
1337(d)(l), (g)(1)) do not preclude issuance of the above-referenced
remedial orders. Additionally, the Commission has determined to impose
a bond of one hundred percent (100%) of the entered value of the
covered products during the period of Presidential review (19 U.S.C.
1337(j)).
The investigation is hereby terminated in its entirety.
The Commission vote for this determination took place on September
12, 2022.
While temporary remote operating procedures are in place in
response to COVID-19, the Office of the Secretary is not able to serve
parties that have not retained counsel or otherwise provided a point of
contact for electronic service. Accordingly, pursuant to Commission
Rules 201.16(a) and 210.7(a)(1) (19 CFR 201.16(a), 210.7(a)(1)), the
Commission orders that the Complainant(s) complete service for any
party/parties without a method of electronic service noted on the
attached Certificate of Service and shall file proof of service on the
Electronic Document Information System (EDIS).
By order of the Commission.
Issued: September 12, 2022.
Katherine Hiner,
Acting Secretary to the Commission.
[FR Doc. 2022-20042 Filed 9-15-22; 8:45 am]
BILLING CODE 7020-02-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on September 16, 2022.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.